EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

NANOBODIES®: A Review of Diagnostic and Therapeutic Applications

Bo-Kyung Jin iD, Steven Odongo, Magdalena Radwanska iD, Stefan Magez iD

International Journal of Molecular Sciences · 22.03.2023 · 24 (6) · 5994

DOI: 10.3390/ijms24065994 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.03.2023. Verfasst von Bo-Kyung Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Biomedical Research, Ghent University Global Campus, Incheon 21985, Republic of Korea. Hauptthemen laut MEDLINE: Single-Domain Antibodies. Die Arbeit wurde bisher 400-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program COMBAT, H2020-EU.3.2.1.1 Program COMBAT grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NANOBODY® (a registered trademark of Ablynx N.V) molecules (Nbs), also referred to as single domain-based VHHs, are antibody fragments derived from heavy-chain only IgG antibodies found in the Camelidae family. Due to their small size, simple structure, high antigen binding affinity, and remarkable stability in extreme conditions, Nbs possess the potential to overcome several of the limitations of conventional monoclonal antibodies. For many years, Nbs have been of great interest in a wide variety of research fields, particularly in the diagnosis and treatment of diseases. This has culminated with the approval of the world’s first Nb based drug (Caplacizumab) in 2018 with others following, and more on the way. This review will provide an overview, with examples, of (i) the structure and advantages of Nbs compared to conventional monoclonal antibodies, (ii) methods used to generate and produce antigen-specific Nbs, (iii) applications for diagnostics, and (iv) ongoing clinical trials for Nb therapeutics as well as promising candidates for clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesAntibodies, MonoclonalPhagocytosisImmunoglobulin G

Stichwörter der Autor:innen

diagnosticstherapeuticsNANOBODY®NANOBODY® generationNANOBODY® production

Substanzen

Single-Domain AntibodiesAntibodies, MonoclonalImmunoglobulin G

Autor:innen und Institutionen

  • Laboratory for Biomedical Research, Ghent University Global Campus, Incheon 21985, Republic of Korea.
  • Department of Biotechnical and Diagnostic Sciences, College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala 7062, Uganda.
  • Center for Biosecurity and Global Health, College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala 7062, Uganda.
  • Department of Biomedical Molecular Biology, Ghent University, B-9052 Ghent, Belgium.
  • Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, B-1050 Brussels, Belgium.
  • Department of Biochemistry and Microbiology, Ghent University, B-9000 Ghent, Belgium.

ORCID-Profile: Bo-Kyung Jin, Magdalena Radwanska, Stefan Magez

Förderung

  • Program COMBAT
  • H2020-EU.3.2.1.1 Program COMBAT grant

Zitieren

APA

Jin, B. K., Odongo, S., Radwanska, M., & Magez, S. (2023). NANOBODIES®: A Review of Diagnostic and Therapeutic Applications. International Journal of Molecular Sciences, 24(6), 5994. https://doi.org/10.3390/ijms24065994

Vancouver

Jin BK, Odongo S, Radwanska M, Magez S. NANOBODIES®: A Review of Diagnostic and Therapeutic Applications. International Journal of Molecular Sciences. 2023;24(6):5994. doi:10.3390/ijms24065994

BibTeX
@article{Jin2023,
  author = {Jin, Bo-Kyung and Odongo, Steven and Radwanska, Magdalena and Magez, Stefan},
  title = {NANOBODIES®: A Review of Diagnostic and Therapeutic Applications},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5994},
  doi = {10.3390/ijms24065994}
}
Kostenlos starten →